

# Martin W Hämmert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5233191/publications.pdf>

Version: 2024-02-01

19  
papers

1,632  
citations

758635

12  
h-index

794141

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1711  
citing authors

#	ARTICLE	IF	CITATIONS
1	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	3.1	686
2	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	3.1	351
3	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	3.1	202
4	Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients. <i>Cells</i> , 2019, 8, 12.	1.8	109
5	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	3.1	84
6	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	41
7	Interference with ERK-dimerization at the nucleocytoplasmic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. <i>Nature Communications</i> , 2020, 11, 1733.	5.8	38
8	Delayed Demyelination and Impaired Remyelination in Aged Mice in the Cuprizone Model. <i>Cells</i> , 2020, 9, 945.	1.8	26
9	Investigation of Oligoclonal IgG Bands in Tear Fluid of Multiple Sclerosis Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1110.	2.2	16
10	Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen. <i>Frontiers in Neurology</i> , 2019, 10, 735.	1.1	14
11	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.5	14
12	Immunophenotyping of cerebrospinal fluid cells by Chipcytometry. <i>Journal of Neuroinflammation</i> , 2018, 15, 160.	3.1	13
13	Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. <i>Brain Sciences</i> , 2021, 11, 296.	1.1	12
14	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	1.7	11
15	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 8527.	1.6	6
16	Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications. <i>Cells</i> , 2022, 11, 2165.	1.8	4
17	Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 87-89.	0.9	2
18	Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 6-7.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110091.	1.5	1